Pharmaceutical Water Systems

Until 2017, Ph. Eur. required WFI to be produced by distillation as the final step. USP had permitted reverse osmosis since 1975 but in practice most global manufacturers ran distillation to maintain a single global facility. In 2017 Ph. Eur. Monograph 0169 was revised to permit WFI by reverse osmosis + ultrafiltration (or equivalent) provided suitable validation; USP followed in 2019, harmonising. The shift opened the door to membrane-WFI systems — lower CAPEX, lower energy, smaller footprint — but added a heavy validation burden: continuous online TOC + conductivity, frequent endotoxin testing, ongoing biofilm risk assessment, and rigorous ozonisation / sanitisation cycles to prevent biofilm.

• Turbulent flow — Reynolds number > 4,000 at all conditions; typical loop velocity 1.0 – 2.0 m/s; prevents stagnant film that hosts biofilm.
• Dead-leg rule — branch lines ≤ 3 × diameter (3D rule under EU; some references 6D under FDA Drug GMP). Longer dead legs become biofilm nurseries.
• Continuous circulation — never static. Loop runs 24/7.
• Hot or cold — hot (80°C+) systems use heat to suppress growth; cold (ambient) systems use ozone or UV. Mixed systems are common.
• Ozonised loops — ozone dosed to 0.02 – 0.2 ppm continuously, degassed at user points; 254 nm UV destroys residual ozone before product contact.
• Sanitisation — periodic (daily / weekly / monthly per design) hot-water (80°C, 1 hour) OR steam (121°C, 30 min) OR chemical (peracetic acid, sodium hypochlorite). Frequency tied to microbial-trend data.
• Materials — 316L stainless, electropolished (Ra < 0.4 μm) for both surface smoothness + corrosion resistance; sanitary-orbital welded joints (boroscope-inspected, documented).
• Sampling points — user points + selected loop points sampled per programme; minimum every user-point on a rotating schedule + every critical-process user-point per batch.

Modern systems run continuous online TOC (USP <643>) + conductivity (USP <645>) at the storage tank outlet + key loop points. Grab-sample microbial + endotoxin testing is performed per the monitoring programme — for WFI typically: every user point at production frequency, full-loop survey weekly to monthly, endotoxin at every user point per WFI batch use. USP <1231> sets alert + action levels — PW action 100 CFU/mL, WFI action 10 CFU/100 mL. Trends above alert trigger investigation; sustained or repeated action-level exceedances trigger loop sanitisation, biofilm review, and potential product hold.

Water-system PQ runs in three phases: Phase 1 (intensive, ~ 2 – 4 weeks) — daily sampling of every user point and selected loop points; build the baseline; tune sanitisation; close out installation defects. Phase 2 (further intensive, ~ 2 – 4 weeks) — same intensity, confirms repeatability. Phase 3 (long-term, 12 months) — routine monitoring frequency; demonstrates seasonal stability across feed-water variation, temperature variation, demand variation. Phase 3 data is the basis for the routine monitoring programme and is reviewed annually.

• Dead leg > 3D / 6D — biofilm forms, intermittent recoveries from the user point; root cause often a poorly-placed sample valve or instrument tap.
• Loop velocity drop during low-demand periods — laminar flow + biofilm; address with continuous recirculation pump sizing + flow-meter alarm.
• Sanitisation cadence relaxed once Phase 3 looks 'clean' — biofilm rebuilds silently; first hit at the EU inspection 2 years later.
• Online TOC sensor never compared to USP <643> off-line standard — sensor drift undetected; data integrity gap.
• Membrane-WFI system run without ozone or with ozone degassing failure — recurrent low-level endotoxin trend that builds to a product-impact event.
• Sample valve not flushed sufficient volume before grab — sample reflects valve contamination, not loop quality.
• Storage tank vent filter not integrity-tested or replaced on schedule — environmental contamination ingress.
• Distillation column changed feed-water profile (new RO membrane, new source) — final WFI conductivity drifts; never trended.
• Loop sampling skipped during shutdowns / changeovers — period of no data; restart-failure not detected promptly.
• Periodic re-qualification (typical annual) deferred during high-production periods — Annex 1 / FDA inspection cite.

• System master: per-loop schematic, sample-point map, sanitisation regime, ozone dose target, sanitisation calendar.
• Online sensor feed: TOC + conductivity + flow + temperature + ozone (where applicable) at storage + loop key points; alert / action thresholds; auto-flag on exceedance.
• Grab-sample scheduler: per-user-point microbial + endotoxin tasks; rotating coverage to hit every user point monthly minimum; per-batch sampling for parenteral campaigns.
• LIMS sample workflow: collection time + analyst e-sig; lab result entry; auto-trend.
• Microbial isolate ID linkage: any positive auto-routes to the microbial-ID workflow; site water-isolate library curated.
• Sanitisation log: per-event start / end + temperature / chemistry / cycle; per-cycle effectiveness assessed against subsequent microbial recoveries.
• Per-batch water-use record: every WO that consumes water from the system links to the loop + grade + sample-result window; recall scoping reaches water-system events.
• Periodic-qualification scheduler: annual + post-sanitisation effectiveness review tasks; APR/PQR water section auto-generated.
• Investigation flow: action-level exceedance triggers OOS workflow, batch-impact scoping, CAPA, and CCS feed (under Annex 1 §2.5).
• Inspection pack: one-click year-of-data export per loop — trends, exceedances, sanitisations, sample results, batch impact — ready for EU / FDA review.